Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying…
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition w…
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates…
. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potentia…